lazertinib
Liquid Biopsy Elucidates Resistance Mechanisms With Targeted Treatment Combo in EGFR-Mutated NSCLC
Premium
Analysis of ctDNA in the MARIPOSA trial showed fewer EGFR alterations and MET amplifications after Rybrevant-Lazcluze treatment than after Tagrisso.
J&J's Rybrevant, Lazcluze Land First-Line FDA Approval for Treating EGFR-Mutant NSCLC
The combination treatment is approved for patients whose lung tumors harbor EGFR exon 19 deletions or exon 21 L858R substitution mutations.
J&J Seeking Frontline Rybrevant-Lazertinib FDA Approval in EGFR-Mutated NSCLC
The application contains data from the Phase III MARIPOSA trial in which the dual anti-EGFR regimen improved outcomes versus AstraZeneca's Tagrisso.
Experts at ESMO said the MARIPOSA studies support Rybrevant combinations as potential options for NSCLC, but survival data and patient stratification are needed.